University of Maryland School of Medicine, Baltimore, MD, United States.
Department of Urology, University of California Irvine, Oakland, CA, United States.
Int J Impot Res. 2021 Apr;33(3):303-310. doi: 10.1038/s41443-020-0263-3. Epub 2020 Mar 23.
Men's Health is a urological subspecialty that is at the forefront of innovation, but little data exist evaluating the attitudes that andrologists have toward the current treatment modalities available for managing Men's Health conditions. A survey of 37 questions asking what providers would choose as treatment for common conditions was distributed online via Survey Monkey to members of the Sexual Medicine Society of North America and European Society for Sexual Medicine. A total of 115 respondents completed the survey after an initial screening question. For erectile dysfunction (ED), 40%, 38%, and 33% of providers indicated that they would use tadalafil daily, tadalafil on demand, or sildenafil on demand, respectively, as first-line phosphodiesterase 5 inhibitor therapy. Furthermore, a total of 74% would elect to undergo low-intensity shockwave therapy [67%], platelet rich plasma injections [15%], and stem cell injections [15%]. Sex/behavioral therapy was preferred for both premature (36%) and delayed (52%) ejaculation. Approximately 44% of respondents indicated that they would undergo Collagenase Clostridium Histolyticum injections for Peyronie's Disease in the acute phase. In the setting of hypogonadal symptoms with borderline low total testosterone levels (300-400 ng/dL), 69% of respondents would pursue testosterone therapy. The prostatic lift procedure was the preferred procedure for men seeking symptom resolution with preservation of ejaculatory function. Many Men's Health specialists would pursue the least invasive options before considering procedural intervention for any given condition. Providers may shift their treatment preferences toward newer treatment modalities as longer term data become available.
男性健康是泌尿科的一个分支领域，处于创新的前沿，但几乎没有数据评估男科医生对当前可用于治疗男性健康状况的治疗方法的态度。一项针对 37 个问题的调查，询问提供者在常见疾病的治疗方案中会选择什么方法，通过 Survey Monkey 在线分发给北美性医学学会和欧洲性医学学会的成员。经过初步筛选问题，共有 115 名受访者完成了调查。对于勃起功能障碍 (ED)，40%、38%和 33%的提供者表示，他们将分别使用他达拉非每日、按需使用他达拉非或按需使用西地那非作为一线磷酸二酯酶 5 抑制剂治疗。此外，共有 74%的人会选择接受低强度冲击波治疗[67%]、富血小板血浆注射[15%]和干细胞注射[15%]。性/行为疗法是治疗早泄（36%）和延迟射精（52%）的首选方法。大约 44%的受访者表示，他们会在急性阶段接受胶原酶溶组织梭菌注射治疗 Peyronie 病。在有低睾酮症状且总睾酮水平（300-400ng/dL）处于边缘低值的情况下，69%的受访者会选择进行睾酮治疗。前列腺提升术是寻求保留射精功能的症状缓解的首选手术。许多男性健康专家在考虑对任何特定疾病进行手术干预之前，会先选择最无创的治疗方案。随着长期数据的出现，提供者可能会将其治疗偏好转向更新的治疗方法。
